Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Immunovia AB ( (SE:IMMNOV) ) just unveiled an announcement.
Immunovia AB reported its interim results for January-March 2025, highlighting a net sales figure of 139 KSEK and a net loss of 57.8 MSEK, attributed to unrealized exchange rate effects. The company is preparing for the September 2025 launch of its PancreaSure test, backed by successful clinical studies and strong interest from stakeholders. Additionally, Immunovia increased its share capital through the exercise of warrants, formed a new Nomination Committee, and is searching for a new CFO to support its commercialization efforts in the USA.
More about Immunovia AB
Immunovia AB is a company focused on early detection of pancreatic cancer, primarily through its diagnostic tests. The company is committed to advancing pancreatic cancer screening and establishing clinical utility, positioning itself for significant growth and market impact.
Average Trading Volume: 3,934,391
Current Market Cap: SEK118.1M
See more data about IMMNOV stock on TipRanks’ Stock Analysis page.